Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Securian Asset Management Inc.

Securian Asset Management Inc. reduced its holdings in Hologic, Inc. (NASDAQ:HOLX) by 2.8% during the 4th quarter, Holdings Channel reports. The firm owned 12,483 shares of the medical equipment provider’s stock after selling 356 shares during the quarter. Securian Asset Management Inc.’s holdings in Hologic were worth $900,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the business. EverSource Wealth Advisors LLC grew its holdings in Hologic by 79.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock valued at $42,000 after purchasing an additional 260 shares during the period. Sequoia Financial Advisors LLC grew its holdings in Hologic by 14.6% in the fourth quarter. Sequoia Financial Advisors LLC now owns 8,468 shares of the medical equipment provider’s stock valued at $610,000 after purchasing an additional 1,080 shares during the period. AGF Management Ltd. grew its holdings in Hologic by 429.4% in the fourth quarter. AGF Management Ltd. now owns 39,825 shares of the medical equipment provider’s stock valued at $2,871,000 after purchasing an additional 32,303 shares during the period. Briaud Financial Planning Inc acquired a new stake in shares of Hologic in the fourth quarter worth approximately $72,000. Finally, Citizens Financial Group Inc. RI acquired a new stake in shares of Hologic in the fourth quarter worth approximately $249,000. 94.73% of the stock is owned by institutional investors and hedge funds.

Hologic Price Performance

NASDAQ:HOLX opened at $60.71 on Friday. Hologic, Inc. has a 52 week low of $60.33 and a 52 week high of $84.67. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. The company has a market capitalization of $13.62 billion, a P/E ratio of 19.15, a P/E/G ratio of 2.14 and a beta of 0.97. The stock’s fifty day moving average is $67.18 and its two-hundred day moving average is $74.68.

Hologic (NASDAQ:HOLX) last posted its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. Equities analysts expect that Hologic, Inc. will post 4.28 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on HOLX. BNP Paribas raised Hologic to a “strong-buy” rating in a research note on Tuesday, December 10th. Argus lowered Hologic from a “buy” rating to a “hold” rating in a research note on Monday, March 3rd. Leerink Partners lowered Hologic from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $80.00 to $75.00 in a research note on Thursday, February 6th. Evercore ISI lowered their price target on Hologic from $76.00 to $73.00 and set an “in-line” rating on the stock in a research note on Thursday, February 6th. Finally, Morgan Stanley lowered their price target on Hologic from $84.00 to $82.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Eleven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $84.62.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.